PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25982816-2	2015	Our study reveals that the TGFBR1 inhibitor SD208 effectively reduces prostate cancer bone metastases.	SD-208	44-49	transforming growth factor beta receptor 1	Homo sapiens	27-33	
16575856-1	2006	OBJECTIVE: To use a specific transforming growth factor beta receptor type I (TGFbetaRI; activin receptor-like kinase 5 [ALK-5]) kinase inhibitor (SD208) to determine the role of activation of the TGFbetaRI kinase (ALK-5) in maintaining the profibrotic phenotype of dermal fibroblasts in systemic sclerosis (SSc).	SD-208	147-152	transforming growth factor beta receptor 1	Homo sapiens	29-119	
21465486-4	2011	Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis.	SD-208	107-113	transforming growth factor beta receptor 1	Homo sapiens	64-68	
21465486-4	2011	Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis.	SD-208	107-113	transforming growth factor beta receptor 1	Homo sapiens	91-95	
18229422-3	2007	Previously, we reported that treatment of pancreatic cancer cells in vitro with SD-208, a small molecule inhibitor of the TGF-beta receptor I kinase (TGF-betaRI), inhibited expression of genes associated with tumor progression and inhibited invasiveness in a cell-based assay.	SD-208	80-86	transforming growth factor beta receptor 1	Homo sapiens	122-148	
18229422-3	2007	Previously, we reported that treatment of pancreatic cancer cells in vitro with SD-208, a small molecule inhibitor of the TGF-beta receptor I kinase (TGF-betaRI), inhibited expression of genes associated with tumor progression and inhibited invasiveness in a cell-based assay.	SD-208	80-86	transforming growth factor beta receptor 1	Homo sapiens	150-160	
16575856-1	2006	OBJECTIVE: To use a specific transforming growth factor beta receptor type I (TGFbetaRI; activin receptor-like kinase 5 [ALK-5]) kinase inhibitor (SD208) to determine the role of activation of the TGFbetaRI kinase (ALK-5) in maintaining the profibrotic phenotype of dermal fibroblasts in systemic sclerosis (SSc).	SD-208	147-152	transforming growth factor beta receptor 1	Homo sapiens	78-87	
32443848-6	2020	Fibrotic phenotype of cardiac microtissues was inhibited by treatment with TGF-beta-receptor type 1 inhibitor SD208 in a dose-dependent manner.	SD-208	110-115	transforming growth factor beta receptor 1	Homo sapiens	75-99